Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

Q4 2024 Earnings Call Transcript February 6, 2025 Illumina, Inc. misses on earnings expectations. Reported EPS is $0.91 EPS, ...

Illumina Inc (ILMN) reports steady revenue growth and strategic advancements, while addressing competitive pressures and geopolitical risks.

CEO Jacob Thaysen highlighted the transformative progress Illumina made in 2024, emphasizing its strategic roadmap targeting high single-digit revenue growth by 2027. He noted significant advancements ...

Core Illumina revenue of $1.1 billion for Q4 2024, up 1% from Q4 2023 on both a reported and constant currency basis; revenue of $4.3 billion for fiscal year 2024, down 2% from fiscal year 2023 on ...

China placed Calvin Klein owner PVH Corp. and US gene sequencing company Illumina Inc. to a so-called blacklist of entities, among a series of retaliatory actions after new tariffs ordered by ...

Feb 4 (Reuters) - Shares of genetic testing company Illumina (ILMN.O), opens new tab and Calvin Klein-owner PVH Corp (PVH.N), opens new tab fell on Tuesday after ...

Chinacategory Xi to chair symposium attended by Jack Ma and other Chinese business leaders, sources say 9:25 AM UTC category China hopes EU to reach 'political decision' on EV tariffs soon ...

and sequenced using Illumina NovaSeq 6000 S4 2×150 bp chemistry. Total reads per sample were 51.43±1.32 million reads/sample, which decreased to 51.40±1.32 million reads/sample (±SEM) on removal of ...